Gittel, Lisa
Li, Jeany Q.
Dell, Jennifer
Wintergerst, Maximilian W. M.
Heinz, Carsten
Finger, Robert P.
Terheyden, Jan Henrik
Funding for this research was provided by:
Deutsche Ophthalmologische Gesellschaft (FF 2019, FF 2019, FF 2019, FF 2019, FF 2019, FF 2019, FF 2019)
Universitätsklinikum Bonn
Article History
Received: 19 December 2023
Accepted: 7 April 2024
First Online: 16 April 2024
Declarations
:
: All data gathered as part of this research project was collected anonymously, obviating the need for approval from the institution’s Ethics Committee. Consequently, written informed consent from participants was not required.
: Not applicable.
: LG: None. JQL: None. JD: None. MWMW: Bayer AG, Berlin-Chemie AG, CenterVue SpA, Carl Zeiss Meditec, Eyenuk, Inc., Eyepress Fachmedien GmbH, glaucare GmbH, Heine Optotechnik GmbH, Heidelberg Engineering, Novartis Pharma GmbH, Optos, Pro Generika e.V., Science Consulting in Diabetes GmbH. CH: Alimera, Bayer, Biogen, Novartis. RPF: Alimera, Apellis, Bayer, Boehringer-Ingelheim, Novartis, ODOS, Oxford Innovation, ProGenerika, Roche/Genentech, Biogen, Icare, Heidelberg Engineering, Zeiss Meditec. JHT: Heidelberg Engineering, Optos, Zeiss, CenterVue, Novartis, Okko.